ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / CAPR / earnings
RLMD (30) RZLT (37) AVTX (17) CTNM (28) ⌘ Pro Terminal →

Capricor Therapeutics Inc. (CAPR) Next Earnings Date & Expected ±12.5% Move

$7.24 +13.48% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $7.40

Capricor Therapeutics Inc. (CAPR) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $370.9M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CAPR Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is CAPR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Capricor Therapeutics Inc. (NASDAQ: CAPR) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $7.24 (+13.48% 1D, market cap $370.9M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 4/20, SEC Balance-Sheet Forensics 12/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, CAPR ranks #625 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does CAPR compare to RLMD and RZLT in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CAPR carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, RLMD (Relmada Therapeutics Inc.) holds a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $381.9M) and RZLT (Rezolute Inc. (NV)) posts a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $382.1M). Among the 5-stock peer group, CAPR leads on earnings multiple (N/A) while CTNM leads on capital efficiency (-29.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CAPR?
▼

Per CAPR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001133869), Capricor Therapeutics Inc. generated $302.8M in revenue (+1259.6% YoY), -$105.0M in net income, and -$72.7M in free cash flow against $355.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $7.40 (+2.24%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.7% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510034
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D
Cash (8)Whales (4)SEC (12)Macro (7)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-10.8% Base Target
$42 Bull$6 Base$5 Bear
📬 FREE CAPR RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CAPR)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (34/100 Composite)
🔍 WHY CAPR SCORES 34/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+12/20 pts (35% of score)

Altman Z-Score 3.38 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Cash Engine Quality+8/20 pts (24% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
26
Grade E$6.88-3.9% Next Q
Q2 (-2Q)
29
Grade E$6.61-7.7% Next Q
Q3 (-1Q)
31
Grade E$6.10+18.7% Next Q
Current
34
Grade E$7.24-8.7% Hist 90D α
Trajectory: E (26) → E (34)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CAPR Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CAPR currently carries a cautious 34/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($8.05) and Max Pain ($7.60) forces dealer call-delta covering toward $42.39.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CAPR• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “CAPR Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 34%NO 66%Trade / Inspect Odds →
NEXT EST. WINDOW: Dec 30, 2026 (~56 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$0.91 Expected Swing
$6.33 (-12.5%)Spot $7.24$8.15 (+12.5%)
MODEL EARNINGS SETUP GAUGE

CAPR Quantitative Pre-Earnings Setup: 34/100

Trailing EPS: $4.25 • YoY Revenue Growth: 12.4%

Model Bullish Setup (34/100)Model Risk Weight (66/100)
Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).
LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

PeriodFiledRevenueNet ProfitFree Cash FlowGross Margin
FY 20252025-12-31$302.8M-$105.0M-$72.7M52%
FY 20242024-12-31$22.3M-$40.5M-$41.2M52%
FY 20232023-12-31$25.2M-$22.3M-$25.6M52%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CAPR)

  • ✓Walkthrough of CAPR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
CAPR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -78.39%▲ RESISTANCE BREAKOUT
2026-11-03O $6.63H $7.24L $6.38C $7.24VOL 3.36M
RES: $3.48SUP: $5.89SMA50: $8.05SMA200: $20.50
$36.71$27.56$18.41$9.27$0.12RES $3.48SUP $5.89$7.242026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CAPR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CAPR Butterfly Map → + Track CAPR →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +1259.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on CAPR today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CAPR. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for CAPR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CAPR)

Health Care Rank #625 of 1015 ⚔️ RLMD vs CAPR Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CAPR vs. RLMD, RZLT, AVTX, CTNM)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Capricor Therapeutics Inc. (CAPR) ranks #625 by composite RQD confidence (34/100, grade E) and #485 by equity capitalization ($370.9M). Within this direct 5-issuer industry benchmark cohort, CAPR leads on earnings valuation at N/A trailing P/E, while CTNM leads on capital efficiency and profitability with -29.0% ROIC and — gross margin. RZLT currently holds the highest overall quantitative score in the immediate peer group at 37/100 (D-) compared with CAPR at 34/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
CAPR ACTIVE
Capricor Therapeutics Inc.
E 34/100 — — -35.0% +13.48% $370.9M Benchmark Subject
RLMD
Relmada Therapeutics Inc.
E 30/100 — — -35.0% +7.26% $381.9M /rlmd-vs-capr →
RZLT
Rezolute Inc. (NV)
D- 37/100 — — -35.0% -1.77% $382.1M /rzlt-vs-capr →
AVTX
Avalo Therapeutics Inc.
E 17/100 — — -35.0% +2.09% $384.5M /avtx-vs-capr →
CTNM
Contineum Therapeutics Inc. (Class A)
E 28/100 — — -29.0% +1.81% $353.3M /ctnm-vs-capr →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001133869 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Capricor Therapeutics Inc. (CAPR) reported GAAP revenue of $302.8M (+1259.6% vs. FY2024 revenue of $22.3M , and +1102.6% cumulative change since FY2023) , GAAP net income of -$105.0M, operating cash flow of -$69.8M, and free cash flow of -$72.7M (-76.7% YoY). On the balance sheet, CAPR closed FY2025 with $355.9M in total assets against $0 in total debt (Altman Z-Score: 3.38, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $302.8M -$105.0M -$69.8M -$72.7M $355.9M —
FY2024 (FY) 2024-12-31 $22.3M -$40.5M -$40.0M -$41.2M $170.5M —
FY2023 (FY) 2023-12-31 $25.2M -$22.3M -$25.6M -$25.6M — —

3. CAPR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CAPR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Capricor Therapeutics Inc. (NASDAQ: CAPR) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $7.24 (+13.48% 1D, market cap $370.9M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 4/20, SEC Balance-Sheet Forensics 12/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, CAPR ranks #625 in composite RQD confidence.

How does CAPR compare to RLMD and RZLT in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CAPR carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, RLMD (Relmada Therapeutics Inc.) holds a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $381.9M) and RZLT (Rezolute Inc. (NV)) posts a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $382.1M). Among the 5-stock peer group, CAPR leads on earnings multiple (N/A) while CTNM leads on capital efficiency (-29.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CAPR?

Per CAPR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001133869), Capricor Therapeutics Inc. generated $302.8M in revenue (+1259.6% YoY), -$105.0M in net income, and -$72.7M in free cash flow against $355.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CAPR trading relative to its 50-day, 200-day, and 52-week technical levels?

CAPR last traded at $7.24 (+13.48% on volume of 5,031,671 shares), positioning the stock -10.06% below its 50-day simple moving average ($8.05) and -64.68% below its 200-day simple moving average ($20.50). Across its 52-week range of $2.96 to $40.37, CAPR sits at the 11.4% percentile with a 14-day RSI of 42.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($6.33 to $8.15).

Direct Sub-Reports: CAPR RQD Cockpit CAPR 12M Forecast CAPR Earnings & Move CAPR Dividends & DRIP CAPR Insiders & 13F CAPR Whale Options CAPR Profit Sankey CAPR News & Why
ROARABLE RATING BRIEF • RQD 34/100 (E) ✓ SEC XBRL & RQD VERIFIED

CAPR — Capricor Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Capricor Therapeutics Inc. (CAPR) earns a live Roarable RQD composite score of 34/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $7.24 (+13.48% 1D, market capitalization $370.9M).

  • Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of -18.86%.
  • Whale 13F & Options Flow (4/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (7/20) + Forensic Balance Sheet (12/20): Incorporates a 1.00x equity beta, Altman Z-Score of 3.38, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Capricor Therapeutics Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating within the Biotechnology: Pharmaceutical Preparations industry..4B. Revenue is reported as — for FY 2025, $22.3M for FY 2024, and $25.2M for FY 2023.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Capricor Therapeutics Inc. (CAPR) reported $302.8M in annual revenue (up from $22.3M in FY2024, +1259.6% YoY) and -$105.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($25.2M revenue, -$22.3M net income) through FY2025, CAPR scaled operating cash flow to -$69.8M and free cash flow to -$72.7M, backed by $355.9M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 34/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -18.86% and institutional whale pillar of 4/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 4/20, sustained execution supports upside toward the upper end of the $2.96 – $40.37 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are therefore — The sector and industry classification (Health Care; Biotechnology: Pharmaceutical Preparations) is the only structural context provided.

  • Key Question #1: Can CAPR sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $302.8M and free cash flow of -$72.7M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is CAPR's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

CAPR Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Capricor Therapeutics Inc. (CAPR) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to CAPR Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

CAPR Bull vs. Bear Conversation Board — What's Your Call at $7.24?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CAPR 🐻 33% BEARISH CONVICTION
1. Pick Your Side on CAPR:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
QU QuantViper RQD DEBATE OPENER • Systematic Momentum Desk 🐂 BULLISH 🎯 Target: $7.40 (+16.0%)
📌 Pinned Debate

A pending November FDA decision on deramiocel and a reported $287.8M cash balance in FY 2025 provide a potential catalyst and funding r

Picked up a starter position in CAPR in my $100K Virtual Cash book at $6.38. A pending November FDA decision on deramiocel and a reported $287.8M cash balance in FY 2025 provide a potential catalyst and funding runway against a $6.63 share price.. Trading inside a $2.96–$40.37 52-week range with -18.86% FCF yield gives solid downside support if Biotechnology: Pharmaceutical Preparations multiples expand this quarter.

VolSurface_Trader 🐂 BULL

@RedlineAuditor Shorting a 4/20 institutional whale-flow stock at $6.38 is dangerous when funds are rotating into Health Care.

RE RedlineAuditor RQD DEBATE OPENER • Accounting Quality Watch 🐻 BEARISH 🎯 Target: $5.04 (-21.0%)
Spot @ $6.38

With a -35% ROIC, -18.86% FCF yield, revenue falling to $0.0M in FY 2025, and a 2/9 Piotroski F-Score, the company shows weak fundament

Fading this rally in CAPR at $6.38. With a -35% ROIC, -18.86% FCF yield, revenue falling to $0.0M in FY 2025, and a 2/9 Piotroski F-Score, the company shows weak fundamentals and limited insider or institutional sponsorship.. With a beta of 1.0 and the stock sitting at $6.38 (52-wk range $2.96–$40.37), the easy multiple expansion is already priced in.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%